In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

For GSK’s Ramakrishnan, who has served as the company's CDTO since 2021, the biggest challenge was helping her company get a ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK’sGSK2.90%increase; green up pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...

GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive ...

Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources ... five years (including joint ventures), with new products such as Shingrix and Arexvy offsetting ...

Partnership is integral to GSK. Bringing people together is the best way to innovate and deliver products that transform the standard of care and improve lives. Over half of GSK’s clinical ...

Nov 19 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called ...